Skip header and navigation

Refine By

14 records – page 1 of 2.

[About All-Russia Congress "Pediatric Cardiology 2002", Moscow, May 29-31, 2002].

https://arctichealth.org/en/permalink/ahliterature184113
Source
Kardiologiia. 2003;43(3):82-3
Publication Type
Conference/Meeting Material
Date
2003

Canadian Task Force for Cardiovascular Science. A Joint Initiative of the Heart and Stroke Foundation of Canada and the Canadian Cardiovascular Society.

https://arctichealth.org/en/permalink/ahliterature220180
Source
Can J Cardiol. 1993 Oct;9(8):699-735
Publication Type
Article
Date
Oct-1993

Changes in cardiovascular deaths and hospitalization in Canada.

https://arctichealth.org/en/permalink/ahliterature169586
Source
Can J Cardiol. 2006 Apr;22(5):425-7
Publication Type
Article
Date
Apr-2006
Author
Norm R C Campbell
Jay Onysko
Helen Johansen
Ru-Nie Gao
Source
Can J Cardiol. 2006 Apr;22(5):425-7
Date
Apr-2006
Language
English
Publication Type
Article
Keywords
Canada - epidemiology
Cardiology - trends
Cardiovascular Diseases - mortality
Forecasting
Health Promotion - organization & administration
Hospitalization - trends
Humans
Preventive Medicine - trends
Notes
Cites: Can J Cardiol. 2000 Feb;16(2):227-910694594
Cites: CMAJ. 2002 Apr 16;166(8):1039-4012002980
Cites: Ann Intern Med. 2003 Jan 7;138(1):24-3212513041
Cites: J Hypertens. 2003 Aug;21(8):1591-712872055
Cites: Circulation. 1994 Mar;89(3):975-908124838
Cites: Hypertension. 2006 Jan;47(1):22-816344380
Cites: BMJ. 2005 Sep 17;331(7517):61416107431
Cites: JAMA. 2005 Oct 12;294(14):1773-8116219880
Cites: Ann Intern Med. 2005 Nov 1;143(9):659-7216263889
Cites: Health Rep. 2005 Nov;17(1):49-5316335693
Cites: CMAJ. 2005 Jul 5;173(1):53-415997045
PubMed ID
16639479 View in PubMed
Less detail

Changes in the patterns of blood pressure treatment in North America from 1960-1990.

https://arctichealth.org/en/permalink/ahliterature219791
Source
J Hum Hypertens. 1993 Dec;7(6):539-41
Publication Type
Article
Date
Dec-1993
Author
J G Fodor
B. Chalati
A S Syed
A. Chockalingam
Author Affiliation
Memorial University of Newfoundland, St. John's, Canada.
Source
J Hum Hypertens. 1993 Dec;7(6):539-41
Date
Dec-1993
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Awareness
Canada
Cardiology - trends
Health Surveys
Humans
Hypertension - therapy
Middle Aged
United States
Abstract
Seven North American surveys investigation a total of 241,725 hypertensives conducted between 1960-90 were reviewed with respect to their treatment status. In 1960 and 1970 nearly half of hypertensives were unaware of their condition and only 16% were treated and well-controlled. During the time period between 1970-1990 the proportion of the 'unaware' respondents declined to 16%, while the proportion of treated and well controlled patients increased to more than 40%. The proportion of those who are treated but the blood pressure fails to be controlled by the therapy to a satisfactory degree remained essentially unchanged, at around 16%. The proportion of those who are aware of their hypertension but are not treated shows a moderately decreasing trend, still representing 16% of all hypertensives in a recent Canadian survey. Although the handling of hypertension as a public health problem is largely successful, one third of patients still don't receive optimal therapy or is not treated at all.
PubMed ID
8114042 View in PubMed
Less detail

[Development of cardiology and specialized cardiologic services in Siberia and the Far East].

https://arctichealth.org/en/permalink/ahliterature237710
Source
Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR. 1986;9(1):15-7
Publication Type
Article
Date
1986

Evidence-based cardiovascular care in the community: a population-based cross-sectional study.

https://arctichealth.org/en/permalink/ahliterature180835
Source
BMC Fam Pract. 2004 Apr 1;5:6
Publication Type
Article
Date
Apr-1-2004
Author
Wayne Putnam
Frederick I Burge
Beverley Lawson
Jafna L Cox
Ingrid Sketris
Gordon Flowerdew
David Zitner
Author Affiliation
Department of Family Medicine, Dalhousie University, Halifax, NS, Canada. wayne.putnam@dal.ca
Source
BMC Fam Pract. 2004 Apr 1;5:6
Date
Apr-1-2004
Language
English
Publication Type
Article
Keywords
Aged
Ambulatory Care - trends
Cardiology - trends
Cardiovascular Agents - therapeutic use
Cross-Sectional Studies
Drug Utilization
Evidence-Based Medicine
Family Practice - trends
Female
Heart Failure - complications - drug therapy
Hospitals, Community - statistics & numerical data
Humans
Male
Middle Aged
Myocardial Ischemia - complications - drug therapy
Nova Scotia
Abstract
Ischaemic heart disease and congestive heart failure are common and important conditions in family practice. Effective treatments may be underutilized, particularly in women and the elderly. The objective of the study was to determine the rate of prescribing of evidence-based cardiovascular medications and determine if these differed by patient age or sex.
We conducted a two-year cross-sectional study involving all hospitals in the province of Nova Scotia, Canada. Subjects were all patients admitted with ischaemic heart disease with or without congestive heart failure between 15 October 1997 and 14 October 1999. The main measure was the previous outpatient use of recommended medications. Chi-square analyses followed by multivariate logistic regression analyses were used to examine age-sex differences.
Usage of recommended medications varied from approximately 60% for beta-blockers and angiotensin converting enzyme (ACE) inhibitors to 90% for antihypertensive agents. Patients aged 75 and over were significantly less likely than younger patients to be taking any of the medication classes. Following adjustment for age, there were no significant differences in medication use by sex except among women aged 75 and older who were more likely to be taking beta-blockers than men in the same age group.
The use of evidence-based cardiovascular medications is rising and perhaps approaching reasonable levels for some drug classes. Family physicians should ensure that all eligible patients (prior myocardial infarction, congestive failure) are offered beta-blockers or ACE inhibitors.
Notes
Cites: Clin Ther. 2002 Sep;24(9):1451-6212380636
Cites: Med Care. 2001 Jun;39(6):575-8711414262
Cites: Fam Pract. 2003 Feb;20(1):22-3112509366
Cites: BMJ. 2003 Jan 25;326(7382):19612543836
Cites: CMAJ. 2003 Mar 4;168(5):553-712615747
Cites: Am J Med. 2003 Feb 15;114(3):211-612641082
Cites: Br J Clin Pharmacol. 2003 Apr;55(4):389-9712680888
Cites: Am J Hypertens. 2003 Jul;16(7):544-812850387
Cites: BMC Fam Pract. 2002 May 3;3:812015819
Cites: Ann Pharmacother. 2003 Dec;37(12):1867-7614632542
Cites: Can J Cardiol. 2004 Jan;20(1):61-714968144
Cites: Arch Intern Med. 1996 Apr 8;156(7):799-8058615714
Cites: Can J Cardiol. 1998 Jun;14 Suppl C:1C-23C9676173
Cites: JAMA. 1998 Aug 19;280(7):623-99718054
Cites: J Am Geriatr Soc. 1999 Feb;47(2):145-509988284
Cites: Can J Cardiol. 1999 Mar;15(3):291-610202192
Cites: Can J Cardiol. 1999 Jul;15(7):787-9610411617
Cites: J Am Geriatr Soc. 1999 Aug;47(8):954-910443856
Cites: Arch Intern Med. 2001 Jun 25;161(12):1521-811427100
Cites: CMAJ. 2001 Jun 12;164(12):1695-611450211
Cites: J Hypertens. 2001 Oct;19(10):1717-2511593090
Cites: N Engl J Med. 2001 Dec 6;345(23):1667-7511759645
Cites: Ann Pharmacother. 2002 May;36(5):751-711978147
Cites: Arch Intern Med. 2002 May 13;162(9):1013-911996611
Cites: CMAJ. 2002 Jun 11;166(12):1525-3012074118
Cites: Can J Cardiol. 2002 Jun;18(6):657-6112107423
Cites: J Hypertens. 2002 Jul;20(7):1297-30212131525
Cites: JAMA. 2002 Jul 24-31;288(4):462-712132976
Cites: Soz Praventivmed. 2002;47(2):128-4212134731
Cites: JAMA. 1999 Dec 1;282(21):2058-6710591389
Cites: N Engl J Med. 2000 Jan 20;342(3):145-5310639539
Cites: CMAJ. 1999 Nov 30;161(11):1403-810906894
Cites: Arch Intern Med. 2001 Jan 22;161(2):183-811176731
Cites: J Am Coll Cardiol. 2002 Nov 20;40(10):1777-8512446061
PubMed ID
15059290 View in PubMed
Less detail

[First results and perspectives in scientific research at the Siberian Division of the All-Union Cardiology Research Center, USSR Academy of Medical Sciences]

https://arctichealth.org/en/permalink/ahliterature74257
Source
Ter Arkh. 1984;56(1):28-32
Publication Type
Article
Date
1984

Ischemic, genetic and pharmacological origins of cardiac arrhythmias: the contribution of the Quebec Heart Institute.

https://arctichealth.org/en/permalink/ahliterature160051
Source
Can J Cardiol. 2007 Oct;23 Suppl B:15B-22B
Publication Type
Article
Date
Oct-2007
Author
Benoît Drolet
Chantale Simard
Laimonis Gailis
Pascal Daleau
Author Affiliation
Quebec Heart Institute, Laval Hospital. benoit.drolet@crhl.ulaval.ca
Source
Can J Cardiol. 2007 Oct;23 Suppl B:15B-22B
Date
Oct-2007
Language
English
Publication Type
Article
Keywords
Arrhythmias, Cardiac - chemically induced - etiology - genetics
Cardiology - trends
Drug-Related Side Effects and Adverse Reactions
Free Radicals
Genetic Predisposition to Disease
Humans
Myocardial Ischemia - complications
Quebec
Risk factors
Abstract
Research in the field of basic electrophysiology at the Quebec Heart Institute (Laval Hospital, Quebec City, Quebec) has evolved since its beginning in the 1990s. Interests were focused on cardiac arrhythmias induced by drugs, allelic variants and metabolic factors produced during ischemia. The results have contributed to the creation of new standards in drug development, more specifically, testing all new drugs for their potential effects on cardiac potassium currents, which could produce life-threatening proarrhythmic effects. In a French-Canadian population, three heterozygous single nucleotide polymorphisms in hK(v)1.5, a gene encoding for a major atrial repolarizing current, were found. These variants affect the expression level of the hK(v)1.5 channel and change the inactivation process in the presence of its accessory beta subunit. Because these effects could shorten atrial action potential, their presence was tested in postcoronary bypass patients and a higher prevalence was found in patients with postoperative atrial fibrillation. Finally, three potentially proarrhythmic factors characteristic of ischemia were identified: pH decrease; oxygen free radicals, which both increase the flow of K(+) ions through human ether-a-go-go-related gene and hK(v)1.5, producing a reduction in action potential duration, frequently leading to cardiac arrhythmias; and lysophosphatidylcholine, a metabolite involved in the production of cardiac arrhythmias early during ischemia that was shown to be a major cause of electrical uncoupling. Over the past decade, the Quebec Heart Institute has provided a significant amount of original data in the field of basic cardiac electrophysiology, specifically concerning arrhythmias originating from pharmacological agents, genetic background and cardiac ischemia.
Notes
Cites: Pflugers Arch. 1987 Aug;409(4-5):394-4023627957
Cites: J Mol Cell Cardiol. 1987 Oct;19 Suppl 5:45-533430644
Cites: Prog Cardiovasc Dis. 1988 Sep-Oct;31(2):115-723047813
Cites: Circ Res. 1988 Nov;63(5):879-923180353
Cites: Circulation. 1989 Jan;79(1):143-532910539
Cites: Circ Res. 1989 Feb;64(2):304-142783564
Cites: Physiol Rev. 1989 Oct;69(4):1049-1692678165
Cites: Am J Physiol. 1990 Feb;258(2 Pt 1):C195-2051689543
Cites: Circ Res. 1990 Apr;66(4):1160-52317892
Cites: Cardiovasc Res. 1990 Feb;24(2):156-642328520
Cites: Am J Cardiol. 1990 Sep 15;66(7):695-82399885
Cites: J Mol Cell Cardiol. 1991 Feb;23 Suppl 1:11-222038071
Cites: Cardiovasc Drugs Ther. 1991 Apr;5(2):515-301854661
Cites: J Lab Clin Med. 1993 Jan;121(1):111-78426072
Cites: Circ Res. 1993 Apr;72(4):879-898443874
Cites: JAMA. 1993 Dec 1;270(21):2590-78230644
Cites: Cardiovasc Res. 1993 Jul;27(7):1237-438252583
Cites: Physiol Rev. 1994 Jan;74(1):139-628295932
Cites: Circ Res. 1994 Jun;74(6):1114-208187277
Cites: N Engl J Med. 1994 Jul 7;331(1):31-88202100
Cites: Circ Res. 1994 Nov;75(5):879-867923634
Cites: J Cardiovasc Pharmacol Ther. 2000 Oct;5(4):267-7311150396
Cites: J Pharmacol Exp Ther. 2001 Apr;297(1):96-10211259532
Cites: Cardiovasc Res. 2001 May;50(2):224-3111334826
Cites: Trends Pharmacol Sci. 2001 May;22(5):240-611339975
Cites: Can J Physiol Pharmacol. 2001 May;79(5):371-811405239
Cites: Circulation. 1995 Jun 15;91(12):3010-67796513
Cites: Circulation. 1996 Feb 1;93(3):407-118565156
Cites: BMJ. 1996 Mar 23;312(7033):731-68605457
Cites: Circ Res. 1996 Aug;79(2):237-468756000
Cites: Circulation. 1996 Oct 1;94(7):1499-5028840835
Cites: Circ Res. 1997 Jun;80(6):782-99168780
Cites: Can J Physiol Pharmacol. 1997 May;75(5):363-79250369
Cites: J Pharmacol Exp Ther. 1997 Oct;283(1):148-569336319
Cites: Circulation. 1998 Jan 20;97(2):204-109445174
Cites: J Pharmacol Exp Ther. 1998 Mar;284(3):1174-99495880
Cites: Pacing Clin Electrophysiol. 1998 May;21(5):1029-349604234
Cites: Pacing Clin Electrophysiol. 1998 May;21(5):1044-579604236
Cites: J Pharmacol Exp Ther. 1999 Feb;288(2):858-659918600
Cites: J Pharmacol Exp Ther. 1999 Mar;288(3):1261-810027867
Cites: Physiol Rev. 1999 Jul;79(3):917-101710390520
Cites: Pflugers Arch. 1999 Aug;438(3):419-2210398876
Cites: J Mol Cell Cardiol. 1999 Jul;31(7):1391-40110403756
Cites: J Am Coll Cardiol. 1999 Aug;34(2):396-40110440151
Cites: J Pharmacol Exp Ther. 1999 Oct;291(1):280-410490914
Cites: Clin Pharmacol Ther. 2005 Mar;77(3):138-4415735608
Cites: Xenobiotica. 2004 Nov-Dec;34(11-12):1013-2315801545
Cites: Biochem Biophys Res Commun. 2005 Jul 15;332(4):1012-915922306
Cites: J Clin Invest. 2005 Aug;115(8):2209-1316025157
Cites: Pflugers Arch. 2005 Aug;450(5):292-715909177
Cites: Cardiovasc Res. 2005 Dec 1;68(3):433-4016109388
Cites: Pflugers Arch. 2006 Jun;452(3):316-2316411137
Cites: Card Electrophysiol Rev. 2002 Sep;6(3):289-9412114854
Cites: Circulation. 2002 Sep 3;106(10):1269-7412208804
Cites: Pflugers Arch. 2002 Oct;445(1):55-912397387
Cites: Prog Cardiovasc Dis. 2003 Mar-Apr;45(5):415-2712704598
Cites: J Cardiovasc Pharmacol. 2003 Jun;41(6):934-712775973
Cites: Arch Mal Coeur Vaiss. 2003 May;96(5):539-4712838849
Cites: Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):479-8614614593
Cites: Circ Res. 2004 Feb 6;94(2):140-514764649
Cites: Circ Res. 2004 Aug 20;95(4):e29-3315297374
Cites: Am J Hum Genet. 2004 Nov;75(5):899-90515368194
Cites: Br J Pharmacol. 1970 Aug;39(4):675-875485144
Cites: J Mol Cell Cardiol. 1978 Jun;10(6):511-2629131
Cites: Circ Res. 1981 Aug;49(2):316-257249269
Cites: Can J Cardiol. 2008 Jan;24(1):41-418209767
Cites: Am J Physiol. 1999 Dec;277(6 Pt 2):H2240-610600842
Cites: J Cardiovasc Electrophysiol. 1999 Dec;10(12):1597-60410636190
Cites: J Mol Cell Cardiol. 2000 Jan;32(1):121-3010652196
Cites: Circ Res. 2000 Feb 4;86(2):152-710666410
Cites: J Cardiovasc Electrophysiol. 2000 Jun;11(6):691-610868744
Cites: J Am Coll Cardiol. 2000 Jul;36(1):1-1210898405
Cites: Circulation. 2000 Jul 18;102(3):275-710899088
Cites: Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10613-810984545
Cites: J Cardiovasc Electrophysiol. 2000 Sep;11(9):1048-5411021476
Cites: Circulation. 2000 Oct 17;102(16):1883-511034933
Cites: Can J Cardiol. 2000 Oct;16(10):1298-30211064304
Cites: Circulation. 2000 Nov 21;102(21):2665-7011085972
Cites: FEBS Lett. 2000 Dec 1;486(1):10-311108833
Cites: Am J Physiol Heart Circ Physiol. 2001 Jan;280(1):H344-5311123250
Cites: Eur Heart J. 2001 Aug;22(16):1511-211482925
Cites: Eur J Clin Pharmacol. 2001 Jun;57(3):229-3411497338
Cites: J Cardiovasc Pharmacol Ther. 2001 Jul;6(3):255-6011584332
Cites: Pflugers Arch. 2001 Oct;443(1):48-5311692265
Cites: Circulation. 2002 Apr 23;105(16):1943-811997281
Cites: Circ Res. 1981 Sep;49(3):815-207261275
Cites: Circ Res. 1984 Mar;54(3):313-226421507
Cites: Eur J Pharmacol. 1986 Jul 31;126(3):179-873758169
Cites: Circ Res. 1987 Aug;61(2):271-93621491
Erratum In: Can J Cardiol. 2009 Mar;25(3):140
PubMed ID
17932583 View in PubMed
Less detail

[Results and trends in development of present-day critical cardiology in N.V. Sklifosovskii Institute of Emergency Care].

https://arctichealth.org/en/permalink/ahliterature202596
Source
Ter Arkh. 1999;71(1):10-4
Publication Type
Article
Date
1999

14 records – page 1 of 2.